Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
1. An isolated nucleic acid encoding a monoclonal neutralizing antibody, or antigen-binding fragment thereof, that specifically interacts with at least one epitope of a Nogo-66 receptor, wherein the antibody, or antigen-binding fragment thereof, comprises:
a VH domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:3, and a VL domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:4; or
a VH domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:5, and a VL domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:6.
2. A vector comprising the isolated nucleic acid of claim 1 , wherein said vector is selected form the group consisting of pcDNA; pTT; pTT3; pEFBOS; pBV; pJV; and pBJ.
3. A host cell transformed with the vector according to claim 2 , wherein the host cell is selected form the group consisting of protist cell, animal cell, plant cell and fungal cell.
4. The host cell of claim 3 wherein the animal cell is a mammalian cell selected form the group comprising HEK293, CHO and COS.
5. A host cell transformed with the vector according to claim 2 , wherein the host cell is a eukaryotic cell.
6. A method of producing a binding protein that binds human and/or rat NgR, the method comprising culturing a host cell in a culture medium under conditions sufficient to produce a binding protein that binds human and/or rat NgR,
wherein the binding protein comprises:
a VH domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:3, and a VL domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:4; or
a VH domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:5, and a VL domain comprising a sequence having at least 90% amino acid sequence identity with SEQ ID NO:6.